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preserved ejection fraction (HFpEF).Background Although diastolic dysfunction is widely considered a key pathophysiologic mediator of HFpEF, the prevalence of
concomitant systolic dysfunction has not been clearly deﬁned.Methods We assessed myocardial systolic and diastolic function in 219 HFpEF patients from a contemporary HFpEF clinical
trial. Myocardial deformation was assessed using a vendor-independent 2-dimensional speckle-tracking software.
The frequency and severity of impaired deformation was assessed in HFpEF, and compared to 50 normal controls
free of cardiovascular disease and to 44 age- and sex-matched hypertensive patients with diastolic dysfunction
(hypertensive heart disease) but no HF. Among HFpEF patients, clinical, echocardiographic, and biomarker
correlates of left ventricular strain were determined.Results The HFpEF patients had preserved left ventricular ejection fraction and evidence of diastolic dysfunction. Compared
to both normal controls and hypertensive heart disease patients, the HFpEF patients demonstrated signiﬁcantly
lower longitudinal strain (LS) (20.0  2.1 and 17.07  2.04 vs. 14.6  3.3, respectively, p < 0.0001 for both)
and circumferential strain (CS) (27.1  3.1 and 30.1  3.5 vs. 22.9  5.9, respectively; p < 0.0001 for both).
In HFpEF, both LS and CS were related to LVEF (LS, R ¼ 0.46; p < 0.0001; CS, R ¼ 0.51; p < 0.0001) but not to
standard echocardiographic measures of diastolic function (E’ or E/E’). Lower LS was modestly associated with
higher NT-proBNP, even after adjustment for 10 baseline covariates including LVEF, measures of diastolic function,
and LV ﬁlling pressure (multivariable adjusted p ¼ 0.001).Conclusions Strain imaging detects impaired systolic function despite preserved global LVEF in HFpEF that may contribute to the
pathophysiology of the HFpEF syndrome. (LCZ696 Compared to Valsartan in Patients With Chronic Heart Failure and
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Impairment in LV diastolic function has been proposed
as a key pathophysiologic mediator (3–5). However, theSee page 457role of concomitant systolic dysfunction despite preserved
left ventricular ejection fraction (LVEF) has not been
well characterized, but may help inform future treatment
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448strategies by deﬁning subpheno-
types in this heterogeneous pop-
ulation. Indeed, prior studies
suggest that LV longitudinal fun-
ction assessed by tissue Doppler
imaging may be impaired in
HFpEF (6–11). However, tissue
Doppler-based assessment of LV
longitudinal function is angle
dependent and typically assesses
only mitral annular motion.
More recently, B-mode speckle
tracking has allowed for quantita-
tive assessment of LV deforma-
tion, and abnormalities of strain
and strain rate have been described
in HFpEF in several small single-
center studies (12–15). We em-
ployed myocardial deformation
imaging to determine the fre-quency, severity, and correlates of impaired systolic function
among patients with HFpEF enrolled in a contemporary
multicenter clinical trial. Speciﬁcally, we hypothesized that
despite preserved LVEF, abnormal strain would be prevalent
in HFpEF, differentiate HFpEF from asymptomatic hyper-
tensive heart disease (HHD), and would relate to levels of N-
terminal pro-brain natriuretic peptide (NT-proBNP),
a soluble biomarker of myocardial wall stress with prognostic
relevance in HFpEF, independent of measures of diastolic
function.Methods
Patient population. The PARAMOUNT (Prospective
Comparison of ARNI With ARB on Management of Heart
Failure With Preserved Ejection Fraction Trial) study
enrolled patients with signs and symptoms of heart failure
(HF), New York Heart Association class II to IV symptoms,
LVEF 45%, and NT-proBNP level >400 pg/ml. Patients
were randomly allocated to receive either the angiotensin-
receptor neprilysin inhibitor (ARNI) LCZ696 or valsartan
over a period of 12 weeks. The study protocol was approved
by all individual site institutional review boards and ethics
committees, and all recruited patients gave written infor-
med consent. Details of the inclusion and exclusion criteria,
study design and primary ﬁndings have been previously
reported (16). Screening NT-proBNP was established by
a tabletop device at point of care, local laboratory, or central
laboratory. No NT-proBNP data were available for the
HHD group or control population.
Control group. We screened the Brigham and Women’s
Hospital’s echocardiography database to retrospectively
identify normal control subjects. Echocardiographic exami-
nations were clinically indicated for 1 of the following
reasons: murmur, evaluation of LV function, syncope, or
atypical chest pain. Normal echocardiograms were deﬁned asnormal LV size and geometry, normal LVEF (>55%),
normal left atrial volume index (LAVi) (<29 ml/m2) (17),
no stenotic valvular lesion, and no abnormal valvular
regurgitation. Electronic medical records were reviewed
for prevalent cardiovascular disease (stroke, coronary ar-
tery disease, myocardial infarction, revascularization, heart
failure, arrhythmia, peripheral artery disease), cardiovascular
risk factors (hypertension, diabetes mellitus, hyperlipidemia,
smoking, renal dysfunction), systemic disease (such as
cancer, infections, autoimmune disorders), or any pharma-
cotherapy. Subjects were excluded if any of these were
identiﬁed. In all, 2,100 echocardiographic examinations and
medical records performed between 2010 and 2012 were
screened to identify 50 controls of similar age and sex
distribution as our HFpEF cohort.
Hypertensive group with diastolic dysfunction but no HF.
We identiﬁed 44 patients with hypertension and diastolic
dysfunction matched to the HFpEF population for age and
sex. They were selected from patients enrolled in
the EXCEED (Exforge Intensive Control of Hypertension to
Evaluate Efﬁcacy in Diastolic dysfunction) trial. Details of the
inclusion and exclusion criteria, study design, and primary
ﬁndings have been previously published (18,19). Brieﬂy, the
EXCEED trial was a multicenter, open-label study of
patients 45 years of age with a history of uncontrolled
systolic hypertension, preserved LVEF (50%), and echo-
cardiographic evidence of diastolic dysfunction. Patients with
HF symptoms, secondary hypertension, diabetes, atrial
ﬁbrillation, a vascular event within the prior 6 months, serum
creatinine >2.0 mg/dl, or nephrotic syndrome were excluded.
All participants underwent echocardiography at enrollment,
which was analyzed centrally by the same core laboratory as the
PARAMOUNT study (Brigham and Women’s Hospital,
Boston, Massachusetts).
Echocardiographic analyses. All sonographers at partici-
pating sites underwent central training in the details of the
echocardiographic views and techniques at study investi-
gator meetings. Echocardiograms were performed at study
enrollment and were sent on digital storage media to the
echocardiography core laboratory at Brigham and Women’s
Hospital. Conventional echocardiographic analysis inclu-
ding 2-dimensional, Doppler, and tissue Doppler were
performed by technicians blinded to clinical information
and treatment assignment using an ofﬂine analysis work
station, as previously described in detail (20). Ventricular
volumes were calculated by the modiﬁed Simpson’s method
using the apical 4- and 2-chamber views, and LVEF was
derived from volumes in the standard manner (17). The
LV mass was calculated from LV linear dimensions and
indexed to body surface area as recommended by American
Society of Echocardiography guidelines. Left ventricular
hypertrophy was deﬁned as LV mass indexed to body surface
area (LVMi) >115 g/m2 in men or >95 g/m2 in women.
The relative wall thickness (RWT) was calculated from LV
end-diastolic dimension and posterior wall thickness. The
left atrial (LA) volume was measured by the biplane
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449area-length method using apical 4- and 2-chamber views at
the end-systolic frame preceding mitral valve opening, and
was indexed to body surface area to derive LAVi. Early
transmitral velocity (E wave) was measured by pulsed wave
Doppler from the apical 4-chamber view with the sample
volume positioned at the tip of the mitral leaﬂets. Tissue
Doppler derived peak longitudinal systolic shortening
velocity (S0) was obtained in the apical 4-chamber view at
the lateral and septal mitral annulus and averaged. Peak left
ventricular relaxation velocity (E’) was obtained from the
lateral and septal mitral annulus and averaged. The E/E’
ratio was calculated as E wave divided by E’ velocities.
Diastolic dysfunction grade was derived from mitral inﬂow
E/A ratio, tissue Doppler septal E’, and deceleration time
(21). All measurements were performed in triplicate.
Digitally acquired baseline echocardiography images
in Digital Imaging and Communications in Medicine
(DICOM) format with acceptable image quality were
uploaded to the TomTec system (Munich, Germany) for
further deformational analyses (Cardiac Performance Anal-
ysis software, TomTec). These methods have been validated
against magnetic resonance imaging and sonomicrometry
(22,23), and we have previously reported excellent repro-
ducibility (24–26). A total of 219 patients of the total
PARAMOUNT patient population of 301 participants
(73% of total enrolled) had adequate echocardiographic
image quality for deformational analysis by B-mode speckle
tracking. Unacceptable image quality was deﬁned as lack of
a full cardiac cycle, >1 segment dropout, digital format other
than DICOM, missing view, or signiﬁcant foreshortening
of the left ventricle. As compared to the 219 patients with
image quality adequate for strain analysis, the 82 excluded
patients were less frequently female (45% vs. 61%), had
a lower prevalence of chronic obstructive pulmonary disease
(6% vs. 16%), a higher prevalence of diabetes (49% vs. 34%),
and a lower LVEF (56% vs. 59%, p ¼ 0.006). No signiﬁcant
differences were noted in other clinical or echocardiographic
measures, including age, NT-proBNP level, LV mass index,
LAVi, E’, and E/E’. (Detailed information on included
and excluded patients are given in Online Table S1.)
For deformation analysis, endocardial borders were traced
at the end-diastolic frame in apical views and at an end-
systolic frame in short-axis views. End diastole was
deﬁned by the QRS complex or as the frame after mitral
valve closure. The software tracks speckles along the endo-
cardial border throughout the cardiac cycle. Peak longitu-
dinal strain (LS) and peak circumferential strain (CS) were
computed automatically generating regional data from 6
segments and an average value for each view. For patients in
sinus rhythm, analyses were performed on a single cardiac
cycle; and for patients in atrial ﬁbrillation, strain values were
calculated as the average of 3 cardiac cycles. Peak average LS
was measured in the apical 4-chamber and apical 2-chamber
views (in 6 segments from each view) and averaged, and
peak average CS was obtained from 6 segments measured in
the short-axis view at the midpapillary level.All strain analysis on HFpEF, HHD, and normal control
subjects were performed by a single investigator. Intra-
observer variability for LS and CS was assessed in a sample
of 30 randomly selected patients. Coefﬁcient of variation
was 6.8% and 8.1% for LS and CS, respectively. Intraclass
correlation coefﬁcients were 0.95 for LS (95% conﬁdence
interval: 0.91 to 0.98) and 0.94 for CS (95% conﬁdence
interval: 0.91 to 0.98).
Statistical analyses. Descriptive statistics for continuous
variables are expressed as mean and standard deviation for
normally distributed variables and median and interquartile
range for non-normally distributed data. Categorical variables
are presented as percentages. Comparison of echocardiographic
measures between HFpEF versus HHD and normal controls
was performed using Student t tests, Wilcoxon rank-sum tests,
or chi-square tests, as appropriate. The relationship between
average LS and CS and clinical characteristics, echocardio-
graphic measures, electrocardiographic parameters, and
NT-proBNP was assessed using linear regression or non-
parametric trend tests. Abnormal LS and CS was deﬁned as
>1 SD or >2 SD below the mean value of normal controls.
The NT-proBNP was log-transformed due to its skewed
distribution. Pearson correlation coefﬁcient was used to
assess the relationships between log-transformed NT-
proBNP and strain measures. Multivariable linear regression
was used to determine the relationship between strain
measures and NT-proBNP after adjustment for potential
confounders. All p values were 2-sided, with p < 0.05 used
to deﬁne statistical signiﬁcance. Statistical analyses were
performed using STATA version 11.2 (Stata Corp., College
Station, Texas).
Results
Of 301 patients randomized in the PARAMOUNT study,
219 (73%) had echocardiographic images in appropriate
format and of adequate quality for speckle-tracking analysis
(Online Table S1). Baseline patient characteristics of the
219 included patients are summarized in Table 1. The
average age was 71  9 years, and the majority of patients
were female, white, and had a history of hypertension. Half
had a history of prior HF hospitalization. In addition
to diuretic use (100%), which was a required inclusion
criterion, rates of therapy with an angiotensin-converting
enzyme inhibitor or angiotensin-receptor blocker (92%)
and beta-blockers (80%) were high. The median NT-
proBNP level was markedly elevated (894 pg/ml, inter-
quartile range: 526 to 1,457 pg/ml).
Among the normal control group (n ¼ 50), the mean age
was 69  7 years, 68% were female, the majority was
white, and their mean body mass index was 25.9 3.9 kg/m2.
All patients in the control group were free of hypertension,
diabetes, hyperlipidemia, smoking, coronary artery disease,
and structural or valvular heart disease, and were not taking
any cardiovascular medication. Echocardiographic analysis
showed normal-sized ventricles, wall thickness, and left
Table 1 Baseline Characteristics According to Quartiles of Longitudinal Strain
Overall
(n ¼ 219)
LS Quartile 1
(n ¼ 55)
LS Quartile 2
(n ¼ 55)
LS Quartile 3
(n ¼ 55)
LS Quartile 4
(n ¼ 54)
p Value
for Trend
Longitudinal strain, % 14.6  3.3 26.5 to 16.5 16.4 to 14.8 14.8 to 12.3 12.2 to 7.4
Clinical characteristics
Age 72 (66–78) 70 (66–76) 74 (70–80) 73 (66–79) 70 (60–78) 0.226
Female 61 67 53 64 59 0.86
White race 83 93 85 89 65 <0.001
Medical history
Hypertension 90 91 93 95 90 0.97
Diabetes mellitus 34 33 33 24 48 0.22
Renal disease,
eGFR<60 ml/kg/1.73 m2
37 38 36 45 28 0.51
Coronary heart disease 42 27 51 47 44 0.11
Prior MI 19 13 27 16 21 0.55
Prior HF hospitalization 50 36 49 53 63 0.006
Systolic BP, mm Hg 136 (128–145) 139 (127–146) 139 (130–147) 136 (124–150) 132 (128–140) 0.46
Diastolic BP, mm Hg 80 (71–84) 75 (68–85) 78 (73–85) 80 (72–82) 80 (75–82) 0.12
Body mass index, kg/m2 29.7 (26.1–33.6) 30.9 (27.2–34.0) 29.1 (25.8–32.9) 29.8 (26.1–36.8) 27.5 (24.6–31.7) 0.03
Body surface area, m2 1.85 (1.68–2.00) 1.90 (1.72–2.03) 1.85 (1.73–1.96) 1.83 (1.70–2.07) 1.75 (1.61–1.95) 0.022
Electrocardiogram
Heart rate, beats/min 66 (60–75) 62 (58–73) 64 (55–74) 68 (60–75) 71 (64–81) 0.001
LBBB 5 2 4 7 9 0.06
Atrial ﬁbrillation 29 35 35 24 22 0.08
Biomarkers
NT-proBNP, pg/ml 894 (526–1,457) 771 (419–1,036) 946 (540–1,454) 999 (582–1,615) 941 (663–2,119) 0.005
Echocardiographic characteristics
LV structure
LVEDVi, ml/m2 58.4 (50.5–67.9) 55.4 (49.4–64.8) 58.6 (50.5–73.0) 57.4 (50.8–66.3) 63.3 (54.6–72.7) 0.034
LVESVi, ml/m2 23.2 (19.1–29.6) 20.5 (16.8–24.6) 22.8 (19.9–30.6) 24.5 (18.1–28.8) 28.7 (22.4–34.3) <0.001
RWT 0.37 (0.33–0.40) 0.37 (0.34–0.41) 0.37 (0.33–0.42) 0.36 (0.32–0.40) 0.36 (0.32–0.40) 0.12
LVMi, g/m2 74.1 (63.2–90.7) 71.0 (60.0–85.8) 75.4 (62.3–95.1) 73.0 (63.2–84.5) 81.1 (66.8–96.0) 0.036
Concentric remodeling, % 13 15 11 13 14 0.92
Concentric hypertrophy, % 8 9 13 4 6 0.24
Eccentric hypertrophy, % 7 4 11 4 10 0.51
Systolic function
LVEF, % 59.2 (53.7–63.6) 63.3 (58.9–67.0) 59.8 (54.1–62.2) 58.1 (53.5–62.7) 54.0 (49.6–59.3) <0.001
LVEF <50% 11 0 5 11 26 <0.001
LVEF 50%–55% 22 11 20 22 34 0.005
LVEF >55% 68 89 75 67 40 <0.001
LV stroke volume, ml 61.4 (52.6–76.5) 66.4 (53.7–82.9) 67.7 (54.6–79.7) 60.5 (51.9–71.7) 59.2 (50.3–71.2) 0.003
S’ mean, cm/s 6.29 (5.24–7.21) 6.51 (5.86–7.66) 6.34 (5.33–7.04) 5.61 (4.96–6.69) 6.25 (4.88–7.24) 0.009
Diastolic function
E’ lateral, cm/s 7.4 (5.4–9.0) 7.3 (5.2–9.4) 7.4 (5.8–8.9) 7.1 (5.3–8.8) 7.5 (5.4–9.2) 0.94
E’ septal, cm/s 5.3 (4.2–6.8) 5.4 (4.4–6.6) 5.2 (4.5–6.8) 5.2 (4.0–7.4) 5.4 (4.2–6.8) 0.64
E/E’ ratio (septal) 14.7 (11.5–18.8) 15.7 (12.1–19.1) 14.2 (11.1–18.1) 14.2 (11.4–20.1) 15.3 (11.5–22.6) 0.84
LAVi, ml/m2 33.9 (26.8–43.0) 34.2 (27.9–45.0) 35.1 (28.1–44.7) 31.5 (24.0–41.2) 34.1 (27.4–40.5) 0.49
Values are mean  SD, median (interquartile range), or n. The p value for trend across quartiles of longitudinal strain (LS) is averaged from apical 4- and 2-chamber views.
BP ¼ blood pressure; E/E’ ratio ¼ mitral inﬂow to mitral relaxation velocity ratio; eGFR ¼ estimated glomerular ﬁltration rate; E’ lateral ¼ lateral mitral relaxation velocity; E’ septal ¼ septal mitral
relaxation velocity; HF ¼ heart failure; LAVi ¼ left atrial volume index; LBBB ¼ left bundle branch block; LVEDVi ¼ left ventricular end-diastolic volume index; LVEF ¼ left ventricular ejection fraction; LVESVi ¼
left ventricular end-systolic volume index; LVMi ¼ left ventricular mass index; MI ¼ myocardial infarction; NT-proBNP ¼ N-terminal pro-brain natriuretic peptide; RWT ¼ relative wall thickness.
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450atrial size (LAVi 21.3  5.5 ml/m2). Left ventricular ejec-
tion fraction was normal (61  3%), and there was no
evidence of diastolic dysfunction (E’ lateral: 9.0  2.2).
Among the 44 age- and sex-matched HHD patients, the
average age was 71  8, 61% were female, the majority was
white, and their mean body mass index was 28.5 4.8 kg/m2.
Mean blood pressure was 165/85 mm Hg. Echocardio-
graphic analysis showed normal-sized ventricles (mean leftventricular end-diastolic volume 100  17 ml) with
preserved LVEF (mean 56  3%). The LV mass index was
73.5  16.1 g/m2. By deﬁnition, all patients had evidence of
diastolic dysfunction with a mean E/E’ of 9.4  2.2 and
LAVi of 26.6  3.7 ml/m2. (A comprehensive summary of
clinical and echocardiographic characteristics of the normal
control, the HHD, and the HFpEF group is provided in
Online Table S2.)
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451Conventional 2-dimensional and Doppler echocardio-
graphic ﬁndings in the overall HFpEF cohort are shown in
Table 1. Diastolic dysfunction was present in 95% of
patients, with 66% having grade II or III diastolic
dysfunction. Median septal E/E’ was 14.7 (11.518.8) and
two-thirds presented with enlarged left atria using a cutoff of
29 ml/m2 (median LAVi 33.9 (26.843.0) ml/m2) (19).
Despite the high prevalence of diastolic abnormalities and
signs of increased LV ﬁlling pressure, LV volumes, mass,
and geometry were normal in most subjects, with only 15%
demonstrating LV hypertrophy and 21% demonstrating
concentric remodeling or hypertrophy.
HFpEF versus controls. Although global systolic pump
function (LVEF) did not differ signiﬁcantly between the
PARAMOUNT study patients and normal controls (59 
8% versus 61  3%, respectively; p ¼ 0.09), HFpEF patients
demonstrated signiﬁcantly lower LS andCS (LS, p< 0.0001;
CS, p< 0.0001) (Fig. 1, Table 2).We observed a relationship
between LVEF and both LS (Pearson correlation ¼ 0.46,
p< 0.001) andCS (Pearson correlation¼0.51, p< 0.001).
However, both LS and CS remained signiﬁcantly lower
among HFpEF patients compared to controls after adjusting
for LVEF (p < 0.001 for both LS and CS) (Fig. 1, Table 2)
and after excluding subjects with LVEF <55% (p < 0.0001
for LS, p ¼ 0.0002 for CS). Patients with evidence of
ischemic heart disease had worse LS and CS as compared
to those HFpEF patients without ischemic heart disease.Figure 1 Average Longitudinal and Circumferential Systolic Strain
Average longitudinal strain (red bars) and circumferential systolic strain (green bars) amon
failure with preserved ejection fraction (HFpEF) patients overall (n ¼ 219), and in 3 categor
controls and between HHD and HFpEF overall for longitudinal strain and circumferential s
to controls.To further investigate the role of ischemic heart disease
in the observed differences in LV deformation, we per-
formed a sensitivity analysis excluding all patients with
a history of myocardial infarction, coronary artery disease,
revascularization procedures, and anginal symptoms, and all
patients with an LVEF <55%. In the remaining 91
patients without any evidence of myocardial ischemia and
an LVEF 55%, both LS and CS remained signiﬁcantly
lower as compared to controls (HFpEF vs. controls:
LS, 15.7 [18.0 to 13.8] vs. 19.9 [21.3 to 18.3],
p < 0.0001; CS, 24.2 [29.0 to 20.4] vs. 26.9
[28.5 to 25.0], p ¼ 0.0007).
HFpEF versus HHD. Compared to HHD, the HFpEF
group demonstrated signiﬁcantly lower LS (p < 0.0001)
and CS (p < 0.0001) (Fig. 1, Table 2). Interestingly,
when compared to controls, the HHD group demon-
strated signiﬁcantly lower LS (p < 0.0001) but higher CS
(p < 0.0001).
Prevalence of abnormal strain in HFpEF. Abnormal LS
and CS was present in 66.7% and 40.4% of HFpEF
patients, respectively, when abnormal was deﬁned as >2 SD
below the mean value of controls (Table 2). In analyses
stratiﬁed by LVEF (<50%, 50% to 55%, and >55%), the
proportion of patients with abnormal LS and CS was
greatest in the lowest LVEF category. The LS was more
frequently abnormal than the CS, a pattern that held across
all LVEF categories (Table 2). The magnitude ofg normal controls (n ¼ 50), hypertensive heart disease (HHD) patients (n¼ 44), heart
ies HFpEF based on left ventricular ejection fraction (LVEF). *p < 0.0001 compared to
train. #p ¼ 0.0002 compared to controls. yLVEF-adjusted p < 0.001 compared
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452impairment in LS was also more prominent than the
magnitude of impairment in CS (average relative reduction
compared to controls of 27% and 15%, respectively).
Longitudinal strain in HFpEF. Worse LS was signiﬁ-
cantly associated with nonwhite race, a history of HF
hospitalization, higher heart rate, ischemic etiology, and
lower LVEF (Table 1). No signiﬁcant association was noted
between LS and sex, cardiovascular comorbidities, or phar-
macotherapy. Importantly, LS was not associated with
systolic or diastolic blood pressure, and 70% of patients with
normal blood pressure at the time of echocardiography
had abnormal LS. Worse LS was signiﬁcantly associated
with lower LVEF (p < 0.001), stroke volume (p ¼ 0.003),
and S’ (p ¼ 0.009). The association with LVEF remained
signiﬁcant when LVEF was stratiﬁed into categories
(LVEF <50%, p < 0.001; LVEF 50% to 55%, p ¼ 0.005;
LVEF >55%, p < 0.001) (Table 1). Worse LS was also
associated with higher LV end-systolic volume index
(p < 0.001), LV end-diastolic volume index (p ¼ 0.03), and
LV mass index (p ¼ 0.04). There was no association
between LS and echocardiographic measures of diastolic
function (Table 1).
Circumferential strain in HFpEF. Patients with worse
CS were more likely to have a history of HF hospitaliza-
tion, coronary heart disease, and prior myocardial infarc-
tion. Worse CS was also associated with lower systolic
blood pressure but not with age, race, or heart rate. Like
LS, lower CS was associated with lower LVEF, lower
stroke volume, and higher LV end-systolic volume index.
The association with LVEF remained signiﬁcant after
stratiﬁcation by LVEF category (LVEF <50%, p < 0.001;
LVEF 50% to 55%, p ¼ 0.012; LVEF >55%, p < 0.001)
(Table 3). There was no association between CS and S’
(p ¼ 0.40). Similar to LS, there was no association bet-
ween CS and measures of diastolic function. The CS was
related to LV geometry, with worse CS being signiﬁcantly
related to lower RWT (Table 3). Similarly, in a multivari-
able model accounting for clinical covariates and echo-
cardiographic measures of cardiac structure and function,
LV mass index was signiﬁcantly associated with CS
(p ¼ 0.02).
Association of strain and NT-proBNP. Worse LS
(modeled both as categorical variable in quartiles and
continuously) was associated with higher NT-proBNP
levels, both when modeled continuously (Pearson correla-
tion 0.20, p ¼ 0.005) (Fig. 2) and categorically (as quartiles;
p for trend ¼ 0.005). The inverse relationship between LS
and NT-proBNP remained signiﬁcant after adjusting for
age, sex, systolic and diastolic blood pressure, body mass
index, LVEF, LAVi, E/E’, atrial ﬁbrillation, and estimated
glomerular ﬁltration rate (adjusted p ¼ 0.001). This robust
relationship also remained signiﬁcant when adjusting for E’
instead of E/E’ (p ¼ 0.001) or when adding E0 (p ¼ 0.001)
or S0 (p ¼ 0.002) to the model. In contrast to LS,
contemporary measures of diastolic function (E0 and LAVi)
were not independently associated with NT-proBNP, nor
Table 3 Baseline Characteristics According to Quartiles of Circumferential Strain
Overall
(n ¼ 146)
CS Quartile 1
(n ¼ 37)
CS Quartile 2
(n ¼ 36)
CS Quartile 3
(n ¼ 38)
CS Quartile 4
(n ¼ 35)
p Value
for trend
Circumferential strain, % 22.9  5.9 40.9 to 25.9 25.9 to 22.1 22.1 to 18.9 18.9 to 11.1
Clinical characteristics
Age 73 (66–79) 74 (67–78) 71 (64–79) 74 (66–78) 72 (66–79) 0.71
Female 62 59 75 63 49 0.24
White race 84 92 75 84 83 0.51
Medical history
Hypertension 90 95 89 89 88 0.40
Diabetes mellitus 37 35 36 37 41 0.61
Renal disease,
eGFR<60 ml/kg/1.73 m2
35 39 19 38 43 0.40
Coronary heart disease 38 30 25 40 59 0.006
Prior MI 17 5 17 16 32 0.005
Prior HF hospitalization 51 27 53 58 66 0.001
Systolic BP, mm Hg 134 (127–144) 140 (132–147) 135 (130–150) 127 (120–140) 133 (128–140) 0.03
Diastolic BP, mm Hg 80 (70–84) 78 (74–85) 80 (70–88) 78 (70–80) 79 (70–83) 0.88
Body mass index, kg/m2 29.9 (25.8–33.6) 30.0 (26.5–34.0) 28.4 (24.3–32.0) 30.9 (26.3–34.5) 30.1 (25.6–32.7) 0.81
Body surface area, m2 1.86 (1.68–2.02) 1.94 (1.72–2.09) 1.75 (1.67–1.95) 1.85 (1.75–1.99) 1.88 (1.66–2.03) 0.74
Electrocardiogram
Heart rate, beats/min 66 (60–75) 63 (59–72) 69 (61–77) 67 (60–75) 68 (60–75) 0.14
Atrial ﬁbrillation 32 30 39 29 31 0.89
Biomarkers
NT- proBNP, pg/ml 945 (513–1,561) 1,036 (540–1,834) 833 (457–1,495) 836 (482–1,459) 951 (726–1,796) 0.86
Echocardiographic characteristics
LV structure
LVEDVi, ml/m2 58.4 (50.7–67.6) 56.5 (49.6–65.1) 58.3 (53.5–68.2) 58.4 (47.9–66.0) 61.5 (50.9–73.8) 0.48
LVESVi, ml/m2 22.9 (19.0–29.4) 20.3 (16.6–24.9) 24.1 (20.0–30.8) 22.6 (19.0–28.9) 28.2 (22.1–35.1) 0.001
RWT 0.36 (0.33–0.41) 0.37 (0.35–0.43) 0.39 (0.34–0.42) 0.35 (0.33–0.40) 0.34 (0.32–0.39) 0.016
LVMi, g/m2 73.8 (62.1–90.6) 73.8 (58.3–91.8) 73.6 (63.3–86.5) 71.8 (62.2–90.6) 75.0 (65.1–90.7) 0.79
Concentric remodeling, % 15 14 23 11 12 0.53
Concentric hypertrophy, % 8 14 6 3 9 0.37
Eccentric hypertrophy, % 7 8 6 8 6 0.83
Systolic function
LVEF, % 59.9 (53.7–64.1) 63.1 (60.5–67.1) 59.1 (54.3–64.3) 59.3 (53.3–62.6) 54.2 (49.6–60.3) <0.001
LVEF <50% 8 0 6 3 27 <0.001
LVEF 50%–55% 24 11 20 32 33 0.014
LVEF >55% 68 89 74 65 39 <0.001
LV stroke volume, ml 61.1 (52.1–78.4) 68.3 (57.7–85.2) 59.7 (55.1–73.1) 61.5 (51.1, 73.2) 56.6 (47.6, 75.7) 0.02
S’ mean, cm/s 6.17 (5.21–7.07) 6.22 (5.49–7.30) 6.11 (5.24–6.91) 6.49 (5.24, 7.21) 5.83 (4.89, 7.35) 0.40
Diastolic function
E’ lateral, cm/s 7.1 (5.1–8.8) 7.0 (5.4–8.7) 7.0 (4.6–10.2) 7.2 (5.2–8.3) 7.4 (5.4–9.4) 0.70
E’ septal, cm/s 5.3 (4.2–7.1) 5.3 (4.3–6.3) 5.2 (4.2–7.4) 5.1 (4.2–7.1) 6.0 (4.0–7.6) 0.88
E/E’ ratio (septal) 14.8 (11.7–19.1) 14.2 (11.2–18.3) 13.8 (11.4–19.0) 15.8 (13.1–22.4) 14.2 (11.7–19.0) 0.55
LAVi, ml/m2 34.4 (27.7–44.1) 33.7 (28.8–45.0) 38.2 (28.1–46.8) 36.5 (28.4–40.9) 33.4 (24.4–44.1) 0.60
Values are mean  SD, median (interquartile range), or n. The p value for trend across quartiles of CS (circumferential strain) is from the parasternal short-axis view.
Abbreviations as in Table 1.
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453was a history of ischemic heart disease or presence of
EF <55%. The inverse association of LS with NT-proBNP,
however, remained signiﬁcant in the subgroup of patients
without ischemic heart disease and with EF 55%. The CS
was not associated with NT-proBNP.Discussion
Principal ﬁndings. This study of 219 patients with
HFpEF enrolled in a contemporary internationalmulticenter clinical trial has 3 major ﬁndings. First, LV LS
and CS are signiﬁcantly reduced in HFpEF compared to
normal controls and to age- and sex-matched hypertensive
patients with diastolic dysfunction. Second, the prevalence
of reduced LS and CS in HFpEF is high. Although LS
and CS are signiﬁcantly related to LVEF, the impairment
in LS and CS in HFpEF persists even when restricted to
patients with EF >55% or to patients without coronary
heart disease. More than half of HFpEF patients with an
LVEF 55% had reduced LS. Neither LS nor CS were
Figure 2
Association of Longitudinal Systolic Strain and
NT-proBNP
Association of longitudinal systolic strain (quartiles) and N-terminal pro-brain
natriuretic peptide (NT-proBNP), geometric means and 95% conﬁdence intervals.
*Trend test performed using log-transformed NT-proBNP data. yAnalysis adjusted
for age, sex, systolic and diastolic blood pressure, body mass index, E/E’, left
ventricular ejection fraction, left atrial volume index, atrial ﬁbrillation, and esti-
mated glomerular ﬁltration rate.
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454related to standard echocardiographic measures of diastolic
function (E’ or E/E’). Third, LS is signiﬁcantly and inde-
pendently associated with NT-proBNP level, a prognosti-
cally relevant biomarker in HFpEF.
Systolic dysfunction in HFpEF. Although LVEF is the
most commonly used and accepted measure of systolic
function, it is highly load dependent and relatively insensi-
tive to subtle abnormalities of LV function (8,27). Indeed,
some studies involving select HFpEF patients have failed
to demonstrate abnormalities in systolic performance, re-
ﬂected in stroke work, preload recruitable stroke work, and
peak (þ)dP/dt (28). In contrast, several other studies eval-
uating multiple noninvasive measures of LV systolic func-
tion by standard echocardiographic techniques, such as LV
midwall fractional shortening or mitral annular plane sys-
tolic displacement, indicate that systolic function may not
be uniformly normal in HFpEF (11,29). The reason for
these discrepancies are unclear but may be related to the
systolic measures evaluated and differences in the HFpEF
patients studied. Early data employing tissue Doppler sug-
gest that longitudinal systolic function may be abnormal
despite preserved LVEF in conditions predisposing to HF
and in HFpEF (6,11). However, tissue Doppler imaging
faces technical limitations including preload and afterload
dependence and is limited in its ability to assesses different
planes of LV deformation other than longitudinal (30). In
addition, prior studies in HFpEF have been largely limited
to single-center experiences with small series of select
patients (12–15).
Speckle-tracking echocardiography is a relatively new
technique, largely independent of angle of incidence,tethering, and cardiac translation, which allows for quanti-
ﬁcation of myocardial deformation in multiple planes.
During systole, the components of LV deformation include
longitudinal shortening, radial thickening, and circumfer-
ential shortening (31). These planes of deformation are
thought to be related to LV myocardial ﬁber orientation,
which is primarily in the longitudinal direction sub-
endocardially and primarily in an oblique orientation sub-
epicardially (32). Our ﬁndings demonstrate a high
prevalence of impaired LV longitudinal function in HFpEF,
even among patients with LVEF >55%, with worse LS
signiﬁcantly related to higher NT-proBNP levels even after
adjusting for LVEF and diastolic measures. NT-proBNP is
a powerful prognostic discriminator in HFpEF (33).
Longitudinal strain predicts outcome in low LVEF patients
independent of LVEF (24,25). Whether impaired longi-
tudinal deformation has prognostic signiﬁcance in HFpEF
remains to be determined.
Our data further suggest impairment in LV circumfer-
ential deformation in HFpEF. Conditions predisposing to
HFpEF, such as hypertension or diabetes, are characterized
by reduced longitudinal strain but an increase in circum-
ferential function (34–36), which has been proposed as
a compensatory mechanism to preserve LVEF (37). Our
ﬁndings suggest that reduced LV CS partially distinguishes
patients with HFpEF from asymptomatic persons with
similar comorbidities. This hypothesis is also supported by
prior studies demonstrating a progressive decrease of global
CS from normal to HFpEF to HFrEF groups even after
adjustment for LV end-systolic wall stress (12).
The underlying pathophysiology in patients with HFpEF
has been commonly believed to involve impairment of dia-
stolic function, with increased passive chamber stiffness
(38,39). However, the marked phenotypic and pathophysi-
ologic heterogeneity characterizing this syndrome is now
well recognized. Traditional noninvasive markers of diastolic
dysfunction are absent in approximately one-third of pati-
ents enrolled in large HFpEF trials (40,41). Indeed, in the
PARAMOUNT trial, although the majority of patients
demonstrated some echocardiographic ﬁndings of diastolic
abnormalities at rest, frankly elevated ﬁlling pressuredbased
on an E/E’ ratio 15dwas present in only 49% of the
patients. Similarly, the prevalence of concentric ventricular
remodeling was very low. These observations suggest that
abnormalities other than concentric hypertrophy and
elevated ﬁlling pressure (assessed as E/É 15 at rest) may
contribute to the pathogenesis of HFpEF. Our ﬁndings of
lower LV strain, a measure of LV systolic function that was
not correlated with diastolic indices, and its independent
association with NT-proBNP suggest a contribution of
systolic dysfunction despite preserved LVEF in at least
a subset of patients with HFpEF.
Study limitations. Strain analysis was not possible in all
patients enrolled in the PARAMOUNT trial, although
no signiﬁcant systematic differences were noted between
patients included or excluded from this analysis. Studies were
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455performed at 65 sites and on echocardiography machines
from a variety of vendors. However, all studies were recorded
digitally, and quantitative analysis was performed centrally
at a blinded core laboratory. All echocardiograms were per-
formed in a resting condition, which limits the ability to
assess the relationship between LS and impaired functional
capacity, an important hallmark of the HFpEF syndrome.
Patients enrolled in this contemporary HFpEF clinical trial
may not be representative of HFpEF patients in the
community, because of speciﬁc clinical trial inclusion and
exclusion criteria. Future studies with clinical outcomes will
be essential to understand the clinical relevance of our
ﬁndings.
Conclusions
Systolic impairment in LV longitudinal and circumferential
deformation is prevalent in HFpEF. Worse LS, in partic-
ular, is associated with higher NT-proBNP. Our ﬁndings
suggest that abnormalities of LV systolic function measured
by strain imaging may contribute to the HFpEF syndrome.
These ﬁndings may help inform future studies to identify
pathophysiologically relevant subgroups of patients within
this heterogeneous syndrome.
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